Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Table 3 Clinical findings of CML patients non-responsive to imatinib therapy and potential biomarkers at the molecular response

Total No	Age (year)	Duration on TKIs (month)	IRIS molecular response (*BCR-ABL1*^ISa)	Relative expression^b of hsa-miR-181a-5p (fold regulation) (collectively = 2.33 down-regulation)	Relative expression^b of hsa-miR-182-5p (fold regulation) (collectively = 2.08 up-regulation)	Relative expression^b of hsa-miR-26a-5p (fold regulation) (collectively = 2.39 up-regulation)
7	20–64	13–142	> 10%	− 41.3405 to 2.0286	−2.3320 to 9.5690	−2.9519 to 12.6264
5	43–64	47–92	≤ 10%	−6.5409 to − 1.3561	−1.5069 to 1.9297	− 1.4556 to 2.6728
6	22–49	11–58	≤ 1%	−4.3154 to −1.0566	− 1.1031 to 2.8252	− 1.5819 to 3.2229
5	21–64	35–131	≤ 0.1%	−4.4367 to − 1.3009	−1.1108 to 4.3120	− 1.3581 to 11.0684
2	36–61	29–109	MR⁴	−1.9178 and 1.0501	4.0233 and 5.8904	5.8497 and 7.4559
2	42–60	26–75	MR^4.5	−2.3776 and 1.1333	1.1474 and 7.1027	1.1083 and 2.7102
1	64	65	undetermined	1.5916	8.1589	13.9131
28	20-64^c (46.04 ± 14.25)^d	11-142^c (61.86 ± 36.33)^d

ISSN: 1471-2407